Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside?

Is TNGX a good stock to buy? We came across a bullish thesis on Tango Therapeutics, Inc. on BioEquity Watch’s Substack. Since the thesis was published on August 28^th, TNGX shares have edged lower as investors weighed updated trial results against the stronger initial data, creating a near-term sentiment headwind while the promising results and planned Phase 3 trial keep the longer-term opportunity in view. In this article, we will summarize the bulls’ thesis on TNGX. Tango...